UK cost agency turns down Bristol drug for head and neck cancer - Reuters

UK cost agency turns down Bristol drug for head and neck cancer Reuters LONDON, April 11 Britain's healthcare cost-effectiveness watchdog NICE said on Tuesday that Bristol-Myers Squibb's immunotherapy drug Opdivo was not worth using on the state health service for treating head and neck cancer due to its high price.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2p0vnvU
via IFTTT